Cymbalta's Expanded GAD Claim Is A Load Off Lilly's Mind
This article was originally published in The Pink Sheet Daily
Approval for maintenance treatment of generalized anxiety disorder may be more about shoring up the blockbuster drug than creating a market for growth.
You may also be interested in...
Lilly continues to evaluate the “marketing mix” for the serotonin-norepinephrine reuptake inhibitor, firm tells “The Pink Sheet” DAILY.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.